D. E. Shaw & Co., Inc. Brainstorm Cell Therapeutics Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCLI
# of Institutions
41Shares Held
10.8MCall Options Held
160KPut Options Held
30.5K-
Armistice Capital, LLC New York, NY6.9MShares$9.79 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$2.15 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA683KShares$969,5980.0% of portfolio
-
Black Rock Inc. New York, NY386KShares$548,7070.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$483,0130.01% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $51.8M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...